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Abstract 
Cisplatin is an effective chemotherapeutic agent indicated in cancer chemotherapy. However, 
its clinical use is associated with peripheral neuropathy that invariably impairs patient quality 
of life. Gabapentin (GBP) is an effective analgesic for neuropathic pain conditions but its 
clinical efficacy in cisplatin-induced neuropathic pain (CINP) is limited, in addition to 
generating unwanted side-effects. In this study, a gabapentin-salicylaldehyde derivative 
[gabapentsal (GPS)] was synthesized and evaluated to explore any potential benefit in 
comparison with GBP in a rat model of CIPN. Administration of cisplatin (3.0 mg/kg/week, 
i.p.) for five consecutive weeks generated reproducible mechanical-allodynia (decreased paw 
withdrawal threshold to von Frey filament application; PWT, g) and thermal hypoalgesia 
(increased nociceptive reaction latency in the hot plate paradigm; s). Treatment with GBP or 
its derivative on the 37
th 
day of the experimental protocol, dose dependently attenuated 
cisplatin-induced nocifensive behaviors. Accordingly, doses of GBP (50-100 mg/kg, i.p.) and 
GPS (25-100 mg/kg, i.p.) suppressed the expression of CINP by normalizing the PWT and 
hot plate response latency 1 h and 3 h post administration. In the rotarod paradigm, GBP at 
all doses markedly impaired motor performance, whilst GPS was devoid of motor 
incoordination except at the highest dose, when a mild impairment occurred. Salicylaldehyde 
alone had no effect on CINP or rotarod performance and neither was there any synergism 
when coadministered with GBP. These findings suggest that both GBP and GPS have 
beneficial effects in the neuropathic pain model though GPS may be potentially more useful 
in the management of CINP. 
Key words Chemotherapy induced neuropathic pain; peripheral neuropathic pain; 
gabapentsal; motor incoordination; rat neuropathic pain model. 
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1. Introduction 
The clinical use of anticancer agents is associated with a number of unwanted side effects 
including neuropathic pain, which is intolerable for the majority of patients (Markman, 2006; 
Stillman and Cata, 2006; Van Cutsem and Arends, 2005). These adverse effects are dose-
dependent and reduce the therapeutic outcome of chemotherapeutic agents worsening patient 
quality of life (Ocean and Vahdat, 2004; Warner, 1995). Cisplatin and its analogues 
(oxaliplatin and carboplatin) are used clinically world-wide as a first-line treatment alone or 
in combination with other antineoplastic agents for malignant tumors including for example, 
those associated with lung, breast and colorectal cancer (He et al., 2016; Lynch et al., 2012; 
Marschner et al., 2015; Zhang et al., 2015). The neuropathy caused by cisplatin may persist 
for years (Chaudhry et al., 2003; Markman, 2003). In addition, approximately 20% of 
patients are unable to complete their course of treatment due to the intolerable neuropathic 
pain arising from the use of antineoplastic agents. The neuropathy caused by such drugs is 
managed by reduction of the cumulative dose, individual doses or sometimes by complete 
cessation of chemotherapy upon the appearance of neuropathic symptoms (Ocean and 
Vahdat, 2004).  
Despite cisplatin combined treatment with a variety of drugs including calcium and 
magnesium infusions, amifostine, antioxidants (glutathione, vitamin E, α-lipoic acid and N-
acetylcysteine) and anticonvulsant or antidepressant drugs (carbamazepine, lamotrigine, 
gabapentin, pregabalin or venlafaxine), clinical outcomes have not been totally satisfactory 
(Albers et al., 2014; Cavaletti and Marmiroli, 2010; Kaley and DeAngelis, 2009). There is 
therefore a need for an effective treatment to prevent or limit the occurrence and severity of 
chemotherapy-induced peripheral neuropathy. 
Gabapentin (Fig.1 A) was first approved by the Medicines and Healthcare products 
Regulatory Agency (MHRA) in 1993 as an oral add-on therapy for the treatment of partial 
seizures and later in 2000 for peripheral neuropathy. It is probably one of the most effective 
agents of the newer generation of antiepileptics used for the treatment of neuropathic pain. 
The efficacy of gabapentin has been demonstrated in clinical trials and in several preclinical 
models of neuropathic pain (Ali et al., 2015; Field et al., 1997; Rowbotham et al., 1998). 
However, there is meager scientific evidence demonstrating gabapentin efficacy against 
cisplatin-induced preclinical neuropathic pain although a previous study has demonstrated 
that it does produce a dose dependent relief of mechanical allodynia in cisplatin-induced 
neuropathic rats (Han et al., 2014). Moreover, gabapentin has been shown to be effective in 
the treatment of cancer-related neuropathic pain, by producing a meaningful reduction in pain 
scores in patients receiving radiotherapy, surgery or chemotherapy (Ross et al., 2005). 
Unfortunately, the effectiveness of systemic GBP in patients suffering from neuropathic pain 
may be limited by the occurrence of side-effects such as dizziness, somnolence, ataxia, 
lethargy and convulsions (Rose and Kam, 2002). Accordingly, the discovery of new drugs 
with enhanced neuropathic pain alleviating propensity associated with a reduced side effect 
profile is warranted.  
In this context, a rationale was adopted in this investigation using a GBP derivative (See 
supplementary file) based on the premise of combining the reported antineuropathic effect of 
GBP (Rosenberg et al., 1997; Serpell and Group, 2002) with the antinociceptive and anti-
inflammatory properties of salicylaldehyde (Rainsford, 2016) in a single molecular entity to 
explore any potential benefit over GBP. The study further investigated the cisplatin-induced 
neuropathic pain de-escalating efficacy of gabapentin in addition to its salicylaldehyde 
derivative (gabapentsal (GPS), Fig.1B) (Mallesha et al., 2012), synthesized herein via an 
exclusively novel method by incorporating a salicylaldehyde moiety at its amine 
functionality. Additionally, a motor coordination assessment (rotarod) was performed to 
evaluate its activity in comparison to GBP. 
 
2. Materials and methods 
2.1. Animals 
Sprague-Dawley rats of either sex (150-200 g) bred in the Animal House of the Department 
of Pharmacy, University of Peshawar, Peshawar, Pakistan, were used in this study. All the 
experimental procedures on animals were performed in compliance with the UK Animals 
(Scientific Procedures) Act 1986 and according to the rules and ethics of the Institutional 
Ethical Committee. Approval for the study was granted with the registration number:10/EC-
15/Pharm. To eliminate bias, all animal groups were coded and both the experimental 
behavior assessors and statistical analysts were blind to the treatments. 
2.2. Acute toxicity test 
For the determination of acute toxicity of GPS, mice were injected intraperitoneally (i.p) with 
GPS at doses ranging from 25-1000 mg/kg (n = 6 mice for each dose) and their behavior was 
observed initially for 2 h and then up to for 24 h post drug administration. The animals were 
observed for spontaneous activity, aggressiveness, cyanosis, ataxia, tail pinch response, 
righting reflex, writhing, convulsions, catalepsy and bizarre behavior (OECD guidelines, 
2001) 
2.3. Induction of cisplatin-induced neuropathic nociception 
Animals were administered cisplatin (3.0 mg/kg i.p., once a week for 5 week, i.e. cumulative 
dose of 15mg/kg). Sterile saline solution (2.0 mL) was administered subcutaneously (s.c.) to 
prevent renal damage via hyperhydration before each cisplatin dose (Authier et al., 2003a; 
Han et al., 2014; McKeage, 1995) and animals received less than 5.0 mL of dosing solution 
into the peritoneal cavity. 
2.3.1. Treatment groups 
2.3.1.1. Experiment 1 (Treatment with GBP) 
GBP was dissolved in normal saline (Zeesol NS,Shahzaib Pharmaceuticals [Pvt.] ltd. Haripur 
Pakistan) and was intraperitoneally administered in doses of 50, 75 and 100 mg/kg on the 37
th
 
day of the treatment protocol. The animals were randomly distributed into the following 
treatment groups (n = 8 rats per group). 
Group 1: Saline (10 mL/kg/week for 5 weeks) + Saline (10 mL/kg on day 37)  
Group 2: Cisplatin (3.0 mg/kg/week for 5 weeks) + Saline (10 mL/kg on day 37) 
Group 3: Cisplatin (3.0 mg/kg/week for 5 weeks) + GBP (50 mg/kg on day 37) 
Group 4: Cisplatin (3.0 mg/kg/week for 5 weeks) + GBP (75 mg/kg on day 37) 
Group 5: Cisplatin (3.0 mg/kg/week for 5 weeks) + GBP (100 mg/kg on day 37) 
Group 6: Saline (10 mL/kg/week for 5 weeks) + GBP (100 mg/kg on day 37) 
2.3.1.2.  Experiment 2 (Treatment with GPS) 
The GBP derivative (GPS) was dissolved in a vehicle comprising of DMSO, Tween-80 and 
normal saline in a ratio of 5:1:94. The animals were randomized into the following treatment 
groups (n = 8 rats per group), during which they were intraperitoneally administered GPS in 
doses of 25, 50, 75 and 100 mg/kg on the 37
th
 day. 
Group 1: Vehicle (10 mL/kg/week for 5 weeks) + Vehicle (10 mL/kg on day 37) 
Group 2: Cisplatin (3.0 mg/kg/week for 5 weeks) + Vehicle (10 mL/kg on day 37) 
Group 3: Cisplatin (3.0 mg/kg/week for 5 weeks) + GBP (100 mg/kg on day 37) 
Group 4: Cisplatin (3.0 mg/kg/week for 5 weeks) + GPS (25 mg/kg on day 37) 
Group 5: Cisplatin (3.0 mg/kg/week for 5 weeks) + GPS (50 mg/kg on day 37) 
Group 6: Cisplatin (3.0 mg/kg/week for 5 weeks) + GPS (75 mg/kg on day 37) 
Group 7: Cisplatin (3.0 mg/kg/week for 5 weeks) + GPS (100 mg/kg on day 37) 
Group 8: Vehicle (10 mL/kg/week for 5 weeks) + GPS (100 mg/kg on day 37) 
2.3.1.3. Experiment 3 (Treatment with salicylaldehyde alone and coadministration of 
salicylaldehyde plus GBP 
Salicylaldehyde (50 and 100 mg/kg) and salicylaldehyde plus GBP (100 + 100 mg/kg, 
coadministeration) were dissolved in normal saline (Zeesol NS, Shahzaib Pharmaceuticals 
[Pvt.] ltd. Haripur Pakistan) and administered intraperitoneally on the 37
th
 day of the 
treatment protocol. The animals were randomly distributed into the following treatment 
groups (n = 8 rats per group). 
Group 1: Saline (10 mL/kg/week for 5 weeks) + Saline (10 mL/kg on day 37) 
Group 2: Cisplatin (3.0 mg/kg/week for 5 weeks) + Saline (10 mL/kg on day 37) 
Group 3: Cisplatin (3.0 mg/kg/week for 5 weeks) + GBP (100 mg/kg on day 37) 
Group 4: Cisplatin (3.0 mg/kg/week for 5 weeks) + GPS (100 mg/kg on day 37) 
Group 5: Cisplatin (3.0 mg/kg/week for 5 weeks) + Salicylaldehyde (50 mg/kg on day 37) 
Group 6: Cisplatin (3.0 mg/kg/week for 5 weeks) + Salicylaldehyde (100 mg/kg on day 37) 
Group 7: Cisplatin (3.0 mg/kg/week for 5 weeks) + GBP + Salicylaldehyde [(100 +100) 
mg/kg, coadministration, on day 37] 
 
2.4. Assessment of static mechanical allodynia 
Animals were tested for static mechanical-allodynia on the 37
th
 day before and after 1 h and 3 
h post-administration of gabapentin, GPS, salicylaldehyde alone or salicylaldehyde plus 
gabapentin (coadministration). A series of 8 von Frey filaments (0.4, 0.70, 1.20, 2.00, 3.63, 
5.50, 8.50, and 15.10 g) (Stoelting, Wood Dale, Illinois, USA) were applied perpendicularly 
to the mid-plantar surface of the left hind paw to an extent that caused the filaments to bend 
(Chaplan et al., 1994). Each von Frey filament was applied for a period of up to 6 s as a cut-
off time or until a positive response occurred. Lifting of the paw or flinching immediately 
upon removal of the filament was recorded as a positive response and a succeeding von Frey 
filament of lower force was applied for the following recording. In the case of an absence of 
response, the subsequent von Frey filament of higher force was applied. This procedure was 
continued until four measurements were taken after the first change in direction (positive 
response) or five consecutive negative responses (2.00, 3.63, 5.50, 8.50 and 15.10-g force) or 
four consecutive positive responses (2.00, 1.20, 0.70, 0.4-g force). A force of 15.10 g was 
selected as the cut-off force at which point further application ceased. von Frey filaments 
were applied at intervals of several seconds to avoid any influence of previous stimuli on 
behavior. Any ambulation was noted as an indefinite response, and the stimulus was repeated. 
The paw withdrawal threshold (PWT, g) was measured in both hind paws with an interval of 
5 min and the mean was calculated from an average of three readings. The pattern of each 
response was converted to the 50% PWT (Shahid et al., 2016). 
2.5. Assessment of thermal nociception  
On the 2
nd
 day of final cisplatin injection (i.e. the 37
th 
protocol day), the animals were tested 
for thermal nociceptive response latency on a hot plate (Harvard apparatus, USA) before, and 
1 h and 3 h post-administration of GBP, GPS, salicylaldehyde alone or salicylaldehyde plus 
GBP (coadministration). The metallic testing plate was maintained at 52.0 ± 0.2 
0
C and the 
response latency in seconds was recorded to the onset of escape jumping or lifting/licking of 
hind paws. In order to avoid tissue injury, a cut-off time limit of 60 seconds was imposed. 
Each response latency was measured in triplicate and the mean value from the three 
measurements was taken as the heat thermal nociceptive response latency (Huang et al., 
2004). 
2.6. Assessment of motor coordination 
An individually designed accelerating rotarod was used in which the animals were placed on 
a rotating drum with the speed increasing from 4 to 40 rpm over 300 s (Shahid et al., 2016). 
The endurance latency for the animals to fall off the rod was measured using a stop watch. 
Animals were trained for 4 days, with three trials per day with a daily increment in the 
maximum time spent on the rotarod from 70 s each trial on day 1 to 300 s per trial on day 4, 
in order to allow rats to memorize the task. During training, any animal that fell off 
prematurely was gently placed back on the rotating drum. On the 4
th
 day, the animals were 
randomly distributed into various groups (n = 8 rats per group) and the baseline was recorded 
by measuring the initial latency to fall off (dismount) the rotating rod. Then the average time 
spent on the rotarod across three trials was measured before (pre-dose) and after 1 h and 3 h 
of treatment with GBP (50, 75 and 100 mg/kg) or GPS (25, 50, 75 and 100 mg/kg), 
salicylaldehyde alone (50 and 100 mg/kg) or salicylaldehyde plus GBP (100 + 100) mg/kg, 
coadministration). 
2.7. Statistical analysis 
Results are presented as mean ± S.E.M. The data in the neuropathic experiments were 
analyzed using two-way repeated measures analysis of variance (ANOVA) followed by post 
hoc Bonferroni test using GraphPad Prism 5 (GraphPad Software Inc. San Diego CA, USA). 
A value of P ≤ 0.05 was accepted as significant. 
 
3. Results 
3.1. Acute toxicity test 
No overt behavioral changes were observed during at an observation time of 2h post GPS 
administration and no mortality occurred at doses up to 1000 mg/kg. 
3.2. Activity of GBP on cisplatin-induced neuropathic static mechano-allodynia  
Weekly administration of cisplatin (3.0 mg/kg) for five weeks resulted in a significant 
reduction (P< 0.001) in the mechanical nociceptive threshold to the innocuous von Frey 
filaments throughout the experimental period. The paw withdrawal threshold decreased from 
13.4 ± 1.2 g (day -1) to 3.8 ± 1.4 g (37
th 
day). Treatment with GBP had a significant main 
dose effect on cisplatin-induced static mechanical allodynia [time = (F (3, 140) = 26.92, P< 
0.0001), treatment = (F (5, 140) = 31.69, P< 0.0001), interaction = (F (15, 140) = 6.73, P< 
0.0001)]. On the 37
th
 day (2
nd 
day after the last cisplatin injection), GBP significantly 
attenuated cisplatin-induced nociception to gentle static pressure stimuli when tested1 h and 3 
h post-doses of 50 mg/kg (P< 0.05, P< 0.01), 75 mg/kg (P< 0.01, P< 0.001) and 100 mg/kg 
(P< 0.001, P< 0.001) respectively. Administration of GBP (100 mg/kg) reversed the 
cisplatin-induced decrease in the nociceptive threshold since a significant increase (P< 0.001) 
in the PWT was observed, compared to cisplatin alone treatment (Fig 2). 
3.3. Effect of the gabapentin derivative (GPS) on cisplatin-induced neuropathic static 
mechano-allodynia 
A single intraperitoneal administration of cisplatin (3.0 mg/kg/week) for 5 consecutive weeks 
generated static mechanical allodynia bilaterally in the hind paws whereby a significant 
decrease (P< 0.001) in the threshold to elicit the paw withdrawal response in response to von 
Frey filaments was observed. The PWT decreased from a baseline PWT value of 14.3 ± 0.7 g 
(day -1) to 1.5 ± 0.5 g on the 37
th
 day. A significant attenuated effect was afforded by the 
treatment on the expression of cisplatin-induced static mechanical allodynia [time = (F (3, 
196) = 72.52, P< 0.0001), treatment = (F (7, 196) = 41.36, P< 0.0001), interaction = (F (21, 
196) = 9.93, P< 0.0001)]. GPS effectively reversed the cisplatin-induced reduction in 
mechanical nociceptive threshold upon application of gentle pressure with von Frey filaments 
to the mid-plantar surface of the bilateral hind paws on the 37
th
 day. Hence post hoc 
comparisons revealed significant anti-allodynic activity at doses of 25 mg/kg (P< 0.01, P< 
0.05), 50 mg/kg (P< 0.001, P< 0.001), 75 mg/kg (P< 0.001, P< 0.001) and 100 mg/kg (P< 
0.001, P< 0.001) when the allodynia paradigm was tested 1 h and 3 h post drug 
administration, respectively. The systemic dose of the positive control, GBP (100 mg/kg), 
allayed the cisplatin-induced neuropathic allodynia by significantly suppressing (P< 0.001) 
the evoked nociceptive response, 1 h and 3 h post drug injection. Additionally, injection of 
GPS to non-cisplatin treated animals had no effect on the nociceptive behavior and when 
compared to the cisplatin positive control, it produced a robust antinociceptive effect (P< 
0.001) throughout the whole testing time-period (Fig 3). 
3.4. Effect of GBP on cisplatin-induced neuropathic thermal hypoalgesia 
Administration of cisplatin (3.0 mg/kg per week) for five consecutive weeks produced 
extensive changes in the perception of thermal nociception such that significant 
thermohypoalgesia (P< 0.001) was observed during testing on the 37
th 
protocol day. 
Consequently, cisplatin increased the nociceptive response latency in the hot plate paradigm 
from a pre-experimental value of 15.6± 2.8s (day -1) to 37.3 ± 4.0s on the concluding 
experimental day (37
th 
day). GBP produced a significant main dose effect on cisplatin-
induced thermohypoalgesia [time = (F (3, 140) = 20.97, P< 0.0001), treatment = (F (5, 140) 
= 15.24, P< 0.0001), interaction = (F (15, 140) = 4.04, P< 0.0001)]. Correspondingly, the 
apparent thermal antinociceptive action of cisplatin on the hot plate was significantly 
diminished by GBP on the37
th 
protocol day 1 h and 3 h post-dosing with 50 mg/kg (P< 0.05, 
P< 0.01), 75 mg/kg (P< 0.01, P< 0.01) and 100 mg/kg (P< 0.001, P< 0.001) respectively. 
GBP (100 mg/kg) by itself did not modify thermal nociceptive behavior as no change in the 
response latency was observed but it intrinsically produced a significant antinociceptive 
response (P< 0.001) versus cisplatin-induced neuropathic thermohypoalgesia (Fig 4). 
 
3.5. Effect of the gabapentin derivative (GPS) on cisplatin-induced neuropathic thermal 
hypoalgesia 
Cisplatin significantly augmented (P< 0.001) the baseline nociceptive threshold evoked by 
the hot plate thermal stimulus on protocol day 37. In consequence, the thermal response 
threshold increased from a pre-experimental latency of 16.6 s to 38.6 s (pre-dose) then up to 
39.8 s (1 h) and 40.8 s (3 h) post-dose on the test day. GPS produced a significant dose effect 
on cisplatin-induced thermal hypoalgesia [time = (F (3, 196) = 48.63, P< 0.0001), treatment 
= (F (7, 196) = 20.36, P< 0.0001), interaction = (F (21, 196) = 3.26, P< 0.0001)]. Thus GPS 
reversed cisplatin hypoalgesia in a dose dependent fashion 1 h and 3 h after administration of 
50 mg/kg (P< 0.05, P< 0.01), 75 mg/kg (P< 0.01, P< 0.001) and 100 mg/kg (P< 0.05, P< 
0.01) respectively on the 37
th
 day. Likewise, the positive control, GBP (100 mg/kg), had a 
significant alleviating action (P< 0.01) on cisplatin escalated thermohypoalgesia. It was also 
noteworthy that on its own, GPS even at the highest dose (100 mg/kg) did not modify the 
baseline threshold nociceptive reaction latency (Fig 5). 
3.6. Activity of GBP and its derivative (GPS) on rotarod performance 
There was a significant main dose effect on motor coordination in rotarod endurance latency  
observed 1 h and 3 h post dosing [time = (F (3, 140) = 94.32, P< 0.0001), treatment = (F (7, 
140) = 30. 64, P< 0.0001), interaction = (F (21, 140) = 10.55, P< 0.0001)]. Hence, GBP 
impaired motor coordination as manifested by a decrease in the rotarod dismount latency at 
50 mg/kg (P< 0.01) and this activity was progressively more pronounced (P< 0.001) at 75 
and 100 mg/kg (i.e. dose related). In comparison, there was no detectable motor 
incoordination on the rotarod to GPS over the dose range 25-75 mg/kg. However, at 100 
mg/kg, GPS did instigate a mild impairment of performance, whereby the animals showed 
decreased dismount latency at 1 h and 3 h. However, this effect was transient (P< 0.05) 
compared to saline treated animals (Fig 6) 
3.7. Activity of salicylaldehyde alone on cisplatin-induced neuropathic static mechano-
allodynia 
Consecutive weekly administration of cisplatin (3.0 mg/kg) for five weeks resulted in a 
significant reduction (P < 0.001) in the mechanical nociceptive threshold to the innocuous 
von Frey filaments (force) throughout the experimental period. The paw withdrawal threshold 
decreased from 14.13 g (day -1) to 2.3 g (37
th 
day). Treatment with salicylaldehyde alone had 
a significant main dose effect on cisplatin-induced static mechanical allodynia [time = (F (3, 
224) = 121.7, P< 0.0001), treatment = (F (7, 224) = 47.15, P< 0.0001), interaction = (F (21, 
224) = 8.6, P< 0.0001)]. On 2
nd
 day of last cisplatin injection (37
th
 protocol day), 
salicylaldehyde did not attenuate cisplatin-induced antinociception to gentle static von Frey 
stimuli when tested 1 h and 3 h post-doses of 50 mg/kg (P> 0.05, P> 0.05), and 100 mg/kg (P 
> 0.05, P > 0.05) respectively. Coadministration of salicylaldehyde plus GBP (100mg + 100 
mg/kg) resulted in an increased paw withdrawal threshold (PWT) at 1 h (P < 0.01) and 3 h (P 
< 0.001) post dosing. Administration of GBP and GPS (100 mg/kg) reversed (P< 0.001) the 
cisplatin-induced fall in the nociceptive threshold since a significant boost (P< 0.001) in the 
PWT was observed, compared to cisplatin alone treatment (Fig 7). 
3.8. Effect of salicylaldehyde alone on cisplatin-induced neuropathic thermal hypoalgesia 
Treatment with cisplatin (3.0 mg/kg per week) for five successive weeks resulted in extensive 
changes in the perception of thermal nociception such that significant thermohypoalgesia (P< 
0.001) was observed during testing on the 37
th 
protocol day. Consequently, cisplatin 
increased the nociceptive response latency in the hot plate paradigm from a pre-experimental 
value of 17.0 s (day -1) to 38.9 s on the concluding experimental day (37
th 
day). 
Salicylaldehyde by itself did not produce any significant effect on cisplatin-induced 
thermohypoalgesia at doses of 50 and 100 mg/kg 1 h (P > 0.05) and 3 h (P > 0.05) post 
administration on the final experimental day. Coadministration of salicylaldehyde and GPS 
(100 + 100 mg/kg) normalized the cisplatin enhanced thermal threshold considerably at 1 h 
(P < 0.05) and 3 h (P < 0.01) post injection. On the other hand, GBP and GPS at doses of 100 
mg/kg shortened the thermal antinociception response time (s) at 1 h (P < 0.05, P < 0.001) 
and 3 h (P < 0.01, P < 0.001) post administration, respectively (Fig 8). 
3.9. Activity of salicylaldehyde alone and salicylaldehyde plus gabapentin on rotarod 
performance 
A significant main dose effect on motor coordination on rotarod dismount latency was  
observed 1 h and 3 h post dosing [time = (F (3, 168) = 114.3, P< 0.0001), treatment = (F (7, 
168) = 75.07, P< 0.0001), interaction = (F (15, 168) = 25.48, P< 0.0001)]. Salicylaldehyde 
alone on the other hand, manifested no modifying effect on rotarod latency at doses of 50 (P> 
0.05) and 100 mg/kg (P>0.05). Coadministration of GBP and salicylaldehyde (100 + 100 
mg/kg) induced a significant decline in the rotarod endurance time (P < 0.001) which was 
comparable to GBP 100 mg/kg (P < 0.001) at 1 h and 3 h post administration. In contrast, 
GPS, at the highest dose used in the experiment, (100 mg/kg) instigated a mild impairment in 
performance (P< 0.05) 1 h and 3 h post administration when compared to saline treated 
animals (Fig 9). 
4. Discussion 
The present study was carried out to evaluate the neuropathic pain alleviating effectiveness of 
GBP and its salicylaldehyde derivative, designated as gabapentsal (GPS), using a refined 
model of cisplatin-induced neuropathic pain in rats (Authier et al., 2003a; Han et al., 2014). 
Chemotherapy-induced peripheral neuropathy (CIPN) is a complication in patients who have 
received a chemotherapeutic agent that is known to be neurotoxic. The platinum compounds 
(cisplatin, carboplatin, oxaliplatin) belong to a commonly used class of neurotoxic 
chemotherapeutic agents which are associated with a length dependent neuropathy that 
primarily affects distal sites, and as doses increase cumulatively, symptoms progress in 
severity to more proximal areas. The sensory signs and symptoms (mild to moderate 
numbness and tingling of hands and feet) typically develop before motor symptoms (rare 
weakness with high doses) and a subset of patients develop painful CIPN (Grisold et al., 
2012). 
Several antineoplastic drugs have been reported to induce peripheral neuropathy in 
experimental animals and these include vincristine (Authier et al., 2003b), paclitaxel 
(Polomano et al., 2001) and cisplatin (Authier et al., 2003a). In this respect, animal models 
have been used to evaluate anticancer drug-induced neuropathies in a search for potential 
therapies to prevent or at least minimize nerve damage (Aley et al., 1996; Authier et al., 
2003a; Nozaki-Taguchi et al., 2001; Polomano et al., 2001). The cisplatin-induced rat model 
of CIPN is currently regarded as being suitable for analgesic efficacy profiling of novel 
compounds and for comparative investigation of the pathobiology of this condition relative to 
that of CIPN induced by other cancer chemotherapy agents (Han et al., 2014). In this study, 
weekly injection of cisplatin (3.0 mg/kg i.p.) for 5 weeks (cumulative dose = 15mg/kg) 
produced reliable mechanical allodynia and thermal hypoalgesia in rat hind paws, which were 
consistent with previous reports concerning the cisplatin-induced neuropathic pain model 
(Authier et al., 2003a; Han et al., 2014). 
It has been demonstrated that cisplatin causes axonal degeneration, particularly in 
subcutaneous tissue of the hind paw and to lesser extent, within the sciatic nerve and lumber 
region of the rat spinal cord in addition to a reduction in peripheral nerve conduction velocity 
(Authier et al., 2003a). Furthermore, chronic administration of cisplatin has been reported to 
be associated with development of mechanical allodynia and hyperalgesia, cold thermal 
allodynia and hyperalgesia, as well as heat thermal hypoalgesia in rats (Authier et al., 2003a; 
Han et al., 2014). In the current study, mechanical allodynia and thermal hypoalgesia were 
selected as the parameter to assess the development of peripheral neuropathic pain because 
low animal stress levels are associated with this model (Vera et al., 2007). Moreover, 
cisplatin dosing is known to be associated with thermal hypoalgesia in the rat hind paw which 
is thought to reflect clinical reports of CIPN in patients. In this instance, development of 
mechanical allodynia and loss of noxious heat sensitivity may well arise from damage to 
myelinated αβ fibers with concurrent depletion of C-fibers (Han et al., 2014). In our study, 
treatment with GBP and GPS limited the expression of mechanical allodynia and 
thermohypoalgesia caused by chronic cisplatin administration. An important issue is to view 
the alterations in the observed nociceptive behaviors (mechanical hyperalgesia and thermal 
hypoalgesia) in relation to the changes in the axons. Mechanical hyperalgesia could be 
attributed to lesions in large fibers that usually exert an inhibitory feedback on small fibers 
(Melzack and Wall, 1967; Wall, 1978) which process mechanical hyperalgesia. Other studies 
have also ascribed the development of mechanical allodynia and loss of noxious heat 
sensitivity to damaged myelinated αβ fibers with concurrent depletion of C-fibers 
(Cavanaugh et al., 2009; Dougherty et al., 2004). GBP has been indicated for the treatment of 
neuropathy, though the exact mechanism through which it inhibits neuropathic pain still 
remains unclear. Evidence suggests that it potentially operates by increasing the level of 
GABA (Kocsis and Honmou, 1994) by acting as a non-NMDA receptor antagonist (Chen et 
al., 2000; Kaneko et al., 2000) and/or by inhibiting the α2δ1 subunit of voltage gated calcium 
channels (Gee et al., 1996; Shimoyama et al., 2000). GBP (and possibly GPS) are multi-
target CNS modulators, acting predominantly on spinal and supraspinal sites of the CNS. 
GBP is a novel anticonvulsant agent that may have a unique effect on voltage dependent Ca
++
 
channel currents at postsynaptic dorsal horn neurons. Furthermore, GBP may interrupt an 
entire series of events, not just a single process that leads to the development of neuropathic 
pain. Preclinical models of anti-inflammatory and neuropathic pain indicate that GBP 
effectively antagonizes the maintenance of this pain (Nicholson, 2000). Several studies 
advocate that GBP does not bind to either GABAA or GABAB receptors (Dooley et al., 1986; 
Suman-Chauhan et al., 1993) nor is it transformed metabolically into GABA (Vollmer et al., 
1986; Taylor et al., 1998; Prakash, 2014). In vitro at higher concentrations, GBP is a mixed 
type inhibitor of GABA-transaminase (Goldlust et al., 1995) and enhances the activity of 
partially purified glutamic acid decarboxylase enzyme (Taylor et al., 1992). In turn, NMR 
spectroscopic data have shown that GABA concentrations in vivo are increased in patients 
receiving GBP (Petroff et al., 1996; Taylor et al., 1992).  It is possible therefore that multiple 
mechanisms are responsible for the anticonvulsant, anxiolytic, neuroprotective (Baydas et al., 
2005) and antinociceptive activity observed in different animal models. In the context of the 
GBP effect on thermal hypoalgesia, a neuroprotective action mediated by glutamate receptor-
independent mechanisms has been reported (Popescu et al., 2013). There is also evidence that 
GBP improves nerve remyelination after chronic sciatic nerve constriction injury (Câmara et 
al., 2015). However, such neuroprotective or regenerative processes mayor may not be 
invoked sufficiently rapidly to modify thermal hypoalgesia within the timeframe of our 
experiments. An alternative explanation therefore may merely implicate motor incoordination 
and/or sedation as an impediment to the nociceptive stimulus response.  
GBP has been demonstrated in several clinical trials to be beneficial against various 
neuropathies including those associated with diabetes, postherpetic neuralgia, and other 
aetiologies (Gilron and Flatters, 2006). However, in a large Phase 3 randomized control trial, 
GBP did not possess positive clinical effects against chemotherapy-induced peripheral 
neuropathy (CIPN) even though a smaller trial had described some efficacy (Rao et al., 
2007). There is therefore, a contrast between the current GBP data in animals and the 
inconsistencies seen clinically. Other animal studies have reported that an up-regulation of 
the α2δ1 subunit of voltage-dependent calcium channels in dorsal root ganglia does not occur 
to nerve injury caused by chemotherapy, but it also does when induced by other insults (Luo 
et al., 2002). Moreover, CIPN patients express a loss of sensation to light touch, pin prick and 
temperature rather than mechanical allodynia (Rao et al., 2007). This may explain why GBP 
appears to be clinically ineffective against CINP in oncology patients and yet it reverses 
mechanical allodynia in rats. 
In this study, a GBP-salicylaldehyde derivative (GPS) was synthesized and its antinociceptive 
effectiveness was assessed in relation to GBP in the cisplatin-induced neuropathic pain model 
in rats. Salicylaldehyde(2-hydroxybenzaldehyde) Schiff base derivatives exhibit a broad 
range of biological activities. They possess promising anti-inflammatory, analgesic (Júnior et 
al., 2011), antiradical (Horackova et al., 2000), antidiabetic (Vančo et al., 2008), antiviral 
(Wang et al., 1990), nematicidal (Caboni et al., 2013), antitumor (Hodnett and Dunn, 1970), 
antifungal (Backes et al., 2014) and antibacterial (Kalaivani et al., 2012) activities. The lack 
of adverse effects up to 1000 mg/kg of GPS indicates that it is safe to the highest tested dose 
used in the in vivo behavioral studies. Treatment with GPS had an attenuating action on 
cisplatin-induced nocifensive behaviors as evidenced by alleviation of mechanical allodynia 
and thermal hypoalgesia at a relatively low dose (25 mg/kg) as well as at higher doses 
equivalent to those of GBP. Moreover, GPS was devoid of any observable side effects 
commonly encountered with the use of GBP such as asthenia, ataxia, (McLean et al., 1999) 
or motor incoordination (Shahid et al., 2016). This was confirmed using the rotarod paradigm 
in which GBP induced considerable impairment of motor coordination. These unwanted 
motoric effects were ostensibly avoided with GPS, though at the highest dose, a transient 
decrease in endurance dismount latency was observed along with retention of antinociceptive 
activity. Similarly, salicylaldehyde, when tested at doses of 50 and 100 mg/kg, it did not 
display any significant effect on cisplatin induced static mechano-allodynia or thermal 
hypoalgesia. Salicylaldehyde was also found to be devoid of any activity on rotarod 
performance. Nevertheless, coadministration of GBP with salicylaldehyde (100 + 100 mg/kg) 
resulted in a decline of the paw withdrawal threshold (static mechano-allodynia) which was 
comparable to that of GBP alone (Fig.7). Also, there was a normalizing effect of the GBP 
plus salicylaldehyde combination on cisplatin induced thermohypoalgesia. The activity of the 
combination was most likely to be attributable to the presence of GBP rather than 
salicylaldehyde which did not manifest any effect on either of the parameters when it was 
administered alone. Performance of animals treated with the combination) on the rotarod also 
expressed motor incoordination analogous to that previously seen with GBP (Shahid et 
al.,2017). CIPN can be extremely painful and disabling, causing considerable loss of 
functional abilities liable to decrease quality of life. The treatment of CIPN remains largely 
ineffective and even though different pharmacological strategies have been attempted, no 
agent has yet been shown to be advantageous. As a result, many patients are forced to dose-
reduce or discontinue potentially curative neurotoxic drugs (Park et al., 2013; Wolf et al., 
2008). This emphasizes the need for new pharmacotherapy with an improved therapeutic 
profile that could prove to be beneficial in the treatment of CIPN. 
5. Conclusion 
Weekly injections of cisplatin (3.0 mg/kg) for five weeks evoked nociceptive sensitivity to 
non-painful tactile stimuli (static mechanical allodynia) and also increased heat nociceptive 
perception (thermohypoalgesia) expressed on the 37
th 
protocol day. GBP and its 
salicylaldehyde derivative (GPS) both suppressed these cisplatin-induced nocifensive 
behaviors as a manifestation of a neuropathic pain alleviating propensity in this rodent model 
of CIPN.  
GPS did not markedly impair the motor performance, as the motor incoordination detected 
with it was of a much lower magnitude than that with GBP in the rotarod assay, 
demonstrating that the observed antinociception was unlikely to have occurred due to motor 
abnormalities. Therefore, GPS may be advantageous in the management of CINP, though 
further clinical and pre-clinical studies are warranted. 
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Figure legends 
 
Fig 1: Chemical structures of gabapentin (GBP) and gabapentsal (GPS). 
 
Figure 2: Effect of single gabapentin (GBP) treatment at 50 mg/kg (GBP-50), 75 mg/kg 
(GBP-75) and 100 mg/kg (GBP-100) on the expression of cisplatin-induced static mechanical 
allodynia [diminished von Frey filament threshold pressure; PWT (g)] in the hind paws after 
5 weekly i.p. injections of cisplatin at 3.0 mg/kg (cisplatin-3) in rats. Data are expressed as 
mean ± S.E.M. of 50% PWT. 
###
P < 0.001 compared to saline treated animals, *P < 0.05, 
**P < 0.01, ***P < 0.001 compared to cisplatin alone treated animals, two-way repeated 
measures ANOVA followed by post hoc Bonferroni analysis. n = 8 rats per group. 
 
Figure 3: Effect of a single treatment with gabapentin (GBP) at 100 mg/kg (GBP-100) and 
its derivative, gabapentsal at 25 mg/kg (GPS-25), 50 mg/kg (GPS-50), 75 mg/kg (GPS-75) 
and 100 mg/kg (GPS-100) on the expression of cisplatin-induced static mechanical allodynia 
[diminished von Frey filament threshold pressure; PWT (g)]in the hind paws after 5 weekly 
i.p. injections of cisplatin at 3.0 mg/kg (cisplatin-3) in rats. Data are expressed as mean ± 
S.E.M. of 50% PWT. 
###
P < 0.001 compared to vehicle treated animals, *P < 0.05, **P < 
0.01, ***P < 0.001 compared to cisplatin alone treated animals, two-way repeated measures 
ANOVA followed by post hoc Bonferroni analysis. n = 8 rats per group. 
 
Figure 4: Effect of a single gabapentin (GBP) treatment at 50 mg/kg (GBP-50), 75 mg/kg 
(GBP-75) and 100 mg/kg (GBP-100) on the expression of cisplatin-induced thermal 
hypoalgesia[increased response latency to the thermal stimulus in the hot plate paradigm 
(s)]after 5 weekly i.p. injections of cisplatin at 3.0 mg/kg (cisplatin-3) in rats. Data are 
expressed as mean ± S.E.M. of reaction latency. 
###
P < 0.001 compared to saline treated 
animals, *P < 0.05, **P < 0.01, ***P < 0.001 compared to cisplatin alone treated animals, 
two-way repeated measures ANOVA followed by post hoc Bonferroni analysis. n = 8 rats per 
group. 
 
Figure 5: Effect of a single treatment with gabapentin (GBP) at 100 mg/kg (GBP-100) and 
its derivative, gabapentsal at 25 mg/kg (GPS-25), 50 mg/kg (GPS-50), 75 mg/kg (GPS-75) 
and 100 mg/kg (GPS-100) on cisplatin-induced thermal hypoalgesia [increased response 
latency to the thermal stimulus in the hot plate paradigm(s)] after 5 weekly i.p. injections of 
cisplatin at 3.0 mg/kg (cisplatin-3) in rats. Data are expressed as mean ± S.E.M. of reaction 
latency. 
###
P < 0.001 compared to vehicle treated animals, *P < 0.05, **P < 0.01, ***P < 
0.001 compared to cisplatin alone treated animals, two-way repeated measures ANOVA 
followed by post hoc Bonferroni analysis. n = 8 rats per group. 
 
Figure 6: Effect of a single treatment with gabapentin (GBP) at 50 mg/kg (GBP-50), 75 
mg/kg (GBP-75), and 100 mg/kg (GBP-100) and its derivative, gabapentsal at 25 mg/kg 
(GPS-25),50 mg/kg (GPS-50), 75 mg/kg (GPS-75) and 100 mg/kg (GPS-100) on rotarod 
performance in rats. Data are expressed as mean ± S.E.M. of endurance latency(s) across 
three test trials. *P < 0.05, ***P < 0.001 compared to vehicle treated animals, two-way 
repeated measures ANOVA followed by post hoc Bonferroni analysis. n = 6 rats per group. 
 
Figure 7: Effect of a single treatment with gabapentin (GBP) at 100 mg/kg (GBP-100) and 
its derivative, gabapentsal at 100 mg/kg (GPS-100), salicylaldehyde 50 mg/kg (Sal-50) and 
100 mg/kg (Sal-100) and coadministration of gabapentin and salicylaldehyde (100 + 100) 
mg/kg  (GBP-100 + Sal-100) on the expression of cisplatin-induced static mechanical 
allodynia [diminished von Frey filament threshold pressure; PWT (g)] in the hind paws after 
5 weekly i.p. injections of cisplatin at 3.0 mg/kg (cisplatin-3) in rats. Data are expressed as 
mean ± S.E.M. of 50% PWT. 
###
P < 0.001 compared to saline treated animals, *P < 0.05, 
**P < 0.01, ***P < 0.001 compared to cisplatin alone treated animals, two-way repeated 
measures ANOVA followed by post hoc Bonferroni analysis. n = 8 rats per group. 
 
Figure 8: Effect of a single gabapentin (GBP) treatment at 100 mg/kg (GBP-100), 
gabapentsal 100 mg/kg (GPS-100), salicylaldehyde 50 mg/kg (Sal-50), 100 mg/kg (Sal-100) 
and coadministration of gabapentin 100 mg/kg plus salicylaldehyde 100 mg/kg (GBP-100 + 
Sal-100) on the expression of cisplatin-induced thermal hypoalgesia [increased response 
latency to the thermal stimulus in the hot plate paradigm (s)] after 5 weekly i.p. injections of 
cisplatin at 3.0 mg/kg (cisplatin-3) in rats. Data are expressed as mean ± S.E.M. of reaction 
latency. 
###
P < 0.001 compared to saline treated animals, *P < 0.05, **P < 0.01, ***P < 
0.001 compared to cisplatin alone treated animals, two-way repeated measures ANOVA 
followed by post hoc Bonferroni analysis. n = 8 rats per group. 
Figure 9: Effect of a single treatment with gabapentin (GBP) at 100 mg/kg (GBP-100),  
gabapentsal at 100 mg/kg (GPS-100), salicylaldehyde 50 mg/kg (Sal-50), salicylaldehyde 100 
mg/kg (Sal-100) and coadministration of gabapentin 100 mg/kg plus salicylaldehyde 100 
mg/kg (GBP-100 + Sal-100) on rotarod performance in rats. Data are expressed as mean ± 
S.E.M. of endurance latency(s) across three test trials. *P < 0.05, ***P < 0.001 compared to 
saline treated animals, two-way repeated measures ANOVA followed by post hoc Bonferroni 
analysis. n = 6 rats per group. 
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